

TDMS No. 88148 - 07

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 04/24/2009

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

F_2_M3

C Number: C88148C

Lock Date: 08/31/2005

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Both

TDMSE Version: 2.1.0

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed			1	
Dosing Accident	1		1	
Moribund Sacrifice	10	11	16	19
Natural Death	4	8	26	31
Survivors				
Terminal Sacrifice	35	31	5	
Missing			1	
Animals Examined Microscopically	50	50	49	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(49)	(50)
Gallbladder	(49)	(50)	(49)	(50)
Intestine Large, Cecum	(50)	(50)	(49)	(50)
Intestine Large, Rectum	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Urethra				1 (2%)
Intestine Small, Duodenum	(50)	(50)	(49)	(50)
Adenoma		1 (2%)		
Intestine Small, Ileum	(50)	(50)	(49)	(50)
Carcinoma			1 (2%)	
Intestine Small, Jejunum	(50)	(50)	(49)	(50)
Carcinoma	2 (4%)		1 (2%)	
Liver	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma		2 (4%)		
Hemangiosarcoma, Multiple	1 (2%)			
Hepatoblastoma	2 (4%)	1 (2%)		
Hepatocellular Adenoma	12 (24%)	14 (28%)	10 (20%)	2 (4%)
Hepatocellular Adenoma, Multiple	10 (20%)	13 (26%)	7 (14%)	
Hepatocellular Carcinoma	14 (28%)	10 (20%)	7 (14%)	
Hepatocellular Carcinoma, Multiple	3 (6%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Hepatocarcinoma	1 (2%)			
Mesentery	(5)	(5)	(4)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (25%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (20%)			
Carcinoma, Metastatic, Uncertain Primary Site				1 (50%)
Carcinoma, Metastatic, Urethra			1 (25%)	
Oral Mucosa	(0)	(1)	(0)	(0)
Pancreas	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Salivary Glands	(50)	(50)	(49)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Squamous Cell Carcinoma		1 (2%)	1 (2%)	3 (6%)
Squamous Cell Papilloma	1 (2%)			1 (2%)
Stomach, Glandular	(50)	(50)	(49)	(50)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach		1 (2%)	1 (2%)	1 (2%)
Tongue	(0)	(1)	(0)	(0)
Tooth	(8)	(3)	(0)	(0)
Odontoma	1 (13%)			
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(49)	(50)
Aorta, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Heart	(50)	(50)	(49)	(50)
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma		1 (2%)		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Hemangiosarcoma, Metastatic, Kidney	1 (2%)			
Subcapsular, Adenoma	3 (6%)	1 (2%)		
Islets, Pancreatic	(50)	(50)	(49)	(50)
Carcinoma	2 (4%)			
Parathyroid Gland	(45)	(47)	(46)	(44)
Pituitary Gland	(49)	(50)	(48)	(50)
Pars Intermedia, Adenoma		1 (2%)		
Thyroid Gland	(50)	(50)	(49)	(50)
C-cell, Carcinoma	1 (2%)			
Follicular Cell, Carcinoma		1 (2%)		
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Coagulating Gland	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		22 (44%)	44 (90%)	48 (96%)
Ductus Deferens	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		23 (46%)	45 (92%)	33 (66%)
Epididymis	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Preputial Gland	(50)	(50)	(49)	(50)
Carcinoma				1 (2%)
Prostate	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		22 (44%)	45 (92%)	49 (98%)
Seminal Vesicle	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		22 (44%)	44 (90%)	48 (96%)
Testes	(50)	(50)	(49)	(50)
Interstitial Cell, Adenoma			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(49)	(50)
Lymph Node	(2)	(1)	(2)	(0)
Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (50%)	
Mediastinal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (50%)	
Mediastinal, Carcinoma, Metastatic, Islets, Pancreatic	1 (50%)			
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Lymph Node, Mesenteric	(50)	(49)	(48)	(50)
Spleen	(50)	(50)	(49)	(49)
Hemangiosarcoma	2 (4%)			
Thymus	(41)	(42)	(40)	(49)
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(49)	(50)
Subcutaneous Tissue, Fibrosarcoma	1 (2%)			
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)	1 (2%)		
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(49)	(50)
Skeletal Muscle	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Urethra		24 (48%)	45 (92%)	49 (98%)
Fibrosarcoma, Metastatic, Skin	1 (2%)			
NERVOUS SYSTEM				
Brain	(50)	(50)	(49)	(50)
Meningioma Malignant	1 (2%)			
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(49)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Alveolar/Bronchiolar Adenoma	4 (8%)	12 (24%)	11 (22%)	5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)	4 (8%)	1 (2%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	1 (2%)	1 (2%)	
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)		3 (6%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra			1 (2%)	
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	5 (10%)	2 (4%)	2 (4%)	
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach		1 (2%)		
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)	1 (2%)	1 (2%)	
Mediastinum, Fibrosarcoma, Metastatic, Skin	1 (2%)			
Nose	(50)	(50)	(49)	(50)
Pleura	(1)	(1)	(1)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (100%)	1 (100%)	
Fibrosarcoma, Metastatic, Skin	1 (100%)			
Trachea	(50)	(50)	(49)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(49)	(50)
Harderian Gland	(50)	(50)	(49)	(50)
Adenoma	6 (12%)	3 (6%)	1 (2%)	1 (2%)
URINARY SYSTEM				
Kidney	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Urethra				1 (2%)
Hemangiosarcoma	1 (2%)			
Ureter	(43)	(45)	(47)	(50)
Carcinoma, Metastatic, Urethra				6 (12%)
Transitional Epithelium, Carcinoma			1 (2%)	
Urethra	(48)	(50)	(49)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Transitional Epithelium, Carcinoma		32 (64%)	46 (94%)	49 (98%)
Urinary Bladder	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Urethra		1 (2%)		3 (6%)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(49)	*(50)
Histiocytic Sarcoma		1 (2%)		
Lymphoma Malignant	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Tumor Summary for Males				
Total Animals with Primary Neoplasms (b)	41	45	46	49
Total Primary Neoplasms	74	101	93	63
Total Animals with Benign Neoplasms	30	32	24	10
Total Benign Neoplasms	38	49	31	10
Total Animals with Malignant Neoplasms	28	42	46	49
Total Malignant Neoplasms	36	52	62	53
Total Animals with Metastatic Neoplasms	9	27	45	49
Total Metastatic Neoplasms	24	121	238	240
Total Animals with Malignant Neoplasms Uncertain Primary Site				1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident	1		1	1
Moribund Sacrifice	6	9	9	21
Natural Death	8	11	8	8
Survivors				
Natural Death				1
Terminal Sacrifice	35	30	32	19
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(49)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Schwannoma Malignant, Metastatic, Skin			1 (2%)	
Gallbladder	(49)	(50)	(50)	(50)
Intestine Large, Cecum	(49)	(50)	(49)	(50)
Fibrosarcoma, Metastatic, Skin				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Intestine Large, Colon	(49)	(50)	(49)	(50)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Intestine Large, Rectum	(49)	(50)	(50)	(50)
Intestine Small, Duodenum	(49)	(50)	(50)	(50)
Carcinoma				1 (2%)
Intestine Small, Jejunum	(49)	(50)	(50)	(50)
Carcinoma				1 (2%)
Leiomyosarcoma		1 (2%)		
Schwannoma Malignant, Metastatic, Skin				1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Liver	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin				2 (4%)
Fibrous Histiocytoma, Metastatic, Skin		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Hepatocellular Adenoma	3 (6%)	9 (18%)	2 (4%)	3 (6%)
Hepatocellular Adenoma, Multiple			1 (2%)	
Hepatocellular Carcinoma	2 (4%)	2 (4%)	1 (2%)	2 (4%)
Schwannoma Malignant, Metastatic, Skin		1 (2%)		1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Mesentery	(5)	(12)	(9)	(15)
Carcinoma, Metastatic, Islets, Pancreatic	1 (20%)			
Fibrosarcoma, Metastatic, Skin				2 (13%)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum		1 (8%)		
Schwannoma Malignant, Metastatic, Skin		1 (8%)		2 (13%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (7%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (11%)	
Pancreas	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin				2 (4%)
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Acinus, Adenoma		1 (2%)		
Salivary Glands	(49)	(50)	(50)	(50)
Squamous Cell Carcinoma			1 (2%)	
Stomach, Forestomach	(49)	(50)	(50)	(50)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma		1 (2%)	1 (2%)	4 (8%)
Squamous Cell Papilloma	2 (4%)	1 (2%)	1 (2%)	
Stomach, Glandular	(49)	(50)	(50)	(50)
Carcinoma				1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				3 (6%)
Tongue	(0)	(1)	(0)	(1)
Squamous Cell Carcinoma				1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Tooth	(2)	(0)	(0)	(0)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(49)	(50)	(50)	(50)
Heart	(49)	(50)	(50)	(50)
Schwannoma Malignant, Metastatic, Skin			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin				1 (2%)
Leiomyosarcoma, Metastatic, Intestine		1 (2%)		
Small, Jejunum				
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Adrenal Medulla	(49)	(50)	(50)	(50)
Pheochromocytoma Malignant	1 (2%)			
Islets, Pancreatic	(49)	(50)	(50)	(50)
Adenoma	1 (2%)			
Carcinoma	1 (2%)			
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Parathyroid Gland	(43)	(47)	(48)	(41)
Pituitary Gland	(49)	(49)	(50)	(50)
Pars Distalis, Adenoma	1 (2%)	1 (2%)	3 (6%)	
Thyroid Gland	(49)	(50)	(50)	(50)
Bilateral, Follicular Cell, Carcinoma	1 (2%)			
C-cell, Adenoma			1 (2%)	
Follicular Cell, Adenoma		2 (4%)		
Follicular Cell, Carcinoma	1 (2%)			1 (2%)
GENERAL BODY SYSTEM				
None				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
GENITAL SYSTEM				
Clitoral Gland	(49)	(50)	(49)	(50)
Carcinoma	1 (2%)	1 (2%)		
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Ovary	(49)	(50)	(50)	(50)
Cystadenoma	2 (4%)			
Fibrosarcoma, Metastatic, Skin				1 (2%)
Hemangioma	1 (2%)			
Luteoma		1 (2%)		1 (2%)
Sarcoma Stromal, Metastatic, Uterus			1 (2%)	
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Teratoma Benign	1 (2%)			
Oviduct	(0)	(0)	(1)	(0)
Uterus	(49)	(50)	(50)	(50)
Carcinoma			1 (2%)	1 (2%)
Fibrosarcoma, Metastatic, Skin				1 (2%)
Hemangiosarcoma		1 (2%)		
Sarcoma Stromal		2 (4%)	1 (2%)	
Cervix, Squamous Cell Carcinoma, Metastatic, Vagina			1 (2%)	
Vagina	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Granular Cell Tumor Benign			1 (2%)	
Sarcoma Stromal, Metastatic, Uterus			1 (2%)	
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Squamous Cell Carcinoma			1 (2%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Lymph Node	(7)	(8)	(9)	(16)
Fibrosarcoma, Metastatic, Skin	1 (14%)			1 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (6%)
Inguinal, Fibrosarcoma, Metastatic, Skin				1 (6%)
Mediastinal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (6%)
Mediastinal, Fibrosarcoma, Metastatic, Skin		1 (13%)	1 (11%)	2 (13%)
Mediastinal, Schwannoma Malignant, Metastatic, Skin		1 (13%)		
Mediastinal, Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (6%)
Pancreatic, Fibrosarcoma, Metastatic, Skin				1 (6%)
Pancreatic, Schwannoma Malignant, Metastatic, Skin		1 (13%)		
Lymph Node, Mandibular	(49)	(49)	(50)	(49)
Lymph Node, Mesenteric	(48)	(49)	(48)	(49)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Spleen	(49)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Skin				2 (4%)
Hemangiosarcoma		1 (2%)		
Thymus	(48)	(48)	(45)	(48)
Fibrosarcoma, Metastatic, Skin				1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Thymoma Benign	1 (2%)			
INTEGUMENTARY SYSTEM				
Mammary Gland	(49)	(50)	(50)	(50)
Skin	(49)	(50)	(50)	(50)
Squamous Cell Papilloma	1 (2%)			
Subcutaneous Tissue, Fibroma			1 (2%)	
Subcutaneous Tissue, Fibrosarcoma	1 (2%)	6 (12%)	5 (10%)	7 (14%)
Subcutaneous Tissue, Fibrosarcoma, Multiple				1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma		1 (2%)		
Subcutaneous Tissue, Mast Cell Tumor				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Benign Subcutaneous Tissue, Mast Cell Tumor				1 (2%)
Malignant Subcutaneous Tissue, Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Subcutaneous Tissue, Schwannoma Malignant	1 (2%)	2 (4%)	2 (4%)	4 (8%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma		1 (2%)		
Skeletal Muscle	(4)	(5)	(1)	(8)
Fibrosarcoma, Metastatic, Skin		2 (40%)		3 (38%)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum		1 (20%)		
Rhabdomyosarcoma	2 (50%)			
Schwannoma Malignant, Metastatic, Skin	1 (25%)		1 (100%)	2 (25%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (13%)
NERVOUS SYSTEM				
Brain	(49)	(50)	(50)	(50)
Peripheral Nerve	(0)	(2)	(1)	(0)
Spinal Cord	(0)	(1)	(1)	(0)
RESPIRATORY SYSTEM				
Lung	(49)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	3 (6%)	6 (12%)	4 (8%)	6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple				1 (2%)
Alveolar/Bronchiolar Carcinoma		2 (4%)	1 (2%)	4 (8%)
Carcinoma, Metastatic, Clitoral Gland	1 (2%)			
Cystic Keratinizing Epithelioma				1 (2%)
Cystic Keratinizing Epithelioma, Multiple				1 (2%)
Fibrosarcoma, Metastatic, Skin		2 (4%)	1 (2%)	3 (6%)
Hepatocellular Carcinoma, Metastatic,	2 (4%)			1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Liver				
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Schwannoma Malignant, Metastatic, Skin			1 (2%)	
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Mediastinum, Fibrosarcoma, Metastatic, Skin			1 (2%)	1 (2%)
Mediastinum, Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Mediastinum, Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Nose	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Ear	(1)	(0)	(1)	(2)
Eye	(49)	(50)	(50)	(49)
Retina, Melanoma Benign				1 (2%)
Harderian Gland	(49)	(50)	(49)	(49)
Adenoma	14 (29%)	6 (12%)	9 (18%)	5 (10%)
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Ureter				1 (2%)
Fibrosarcoma, Metastatic, Skin				2 (4%)
Ureter	(0)	(1)	(0)	(2)
Transitional Epithelium, Carcinoma				1 (50%)
Urethra	(49)	(50)	(49)	(49)
Transitional Epithelium, Carcinoma				2 (4%)
Urinary Bladder	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Urethra				1 (2%)
Carcinoma, Metastatic, Uterus			1 (2%)	
Fibrosarcoma, Metastatic, Skin				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
SYSTEMIC LESIONS				
Multiple Organs	* (50)	* (50)	* (50)	* (50)
Histiocytic Sarcoma	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Lymphoma Malignant	2 (4%)	5 (10%)	8 (16%)	7 (14%)
Mesothelioma Malignant			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 14:57:52

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Tumor Summary for Females				
Total Animals with Primary Neoplasms (b)	29	37	34	38
Total Primary Neoplasms	44	56	47	61
Total Animals with Benign Neoplasms	24	23	20	17
Total Benign Neoplasms	30	27	23	20
Total Animals with Malignant Neoplasms	13	23	21	33
Total Malignant Neoplasms	14	29	24	41
Total Animals with Metastatic Neoplasms	7	6	8	12
Total Metastatic Neoplasms	11	18	22	58
Total Animals with Malignant Neoplasms Uncertain Primary Site				1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors